Bipartisan House Lawmakers Press Trump Administration for Answers on Schedule III Marijuana Rollout
- A bipartisan group of House lawmakers requested clarity from the Trump administration on implementing the new Schedule III framework for certain medical marijuana products, addressing impacts on patients, businesses, taxes, healthcare coverage, and federal enforcement.
- The lawmakers highlighted the need for guidance on patient rights, worker protections, home cultivation, healthcare coverage, and the new DEA registration system following the Department of Justice’s partial rescheduling order under the Controlled Substances Act.
- Key questions include the federal classification of patient-cultivated marijuana, Medicare coverage for Schedule III products, tax implications for businesses operating in both medical and recreational markets, and how non-registered businesses and patients will be treated under federal enforcement.
- The letter also requests details on DEA registration processes, privacy safeguards for collected information, and stresses the importance of ongoing engagement to develop a clear and consistent federal marijuana policy.
A bipartisan group of House lawmakers is asking the Trump administration to clarify how the federal government will implement its new Schedule III framework for certain medical marijuana products, including how the change will affect patients, businesses, taxes, healthcare coverage and federal enforcement.
In an August 18 letter, Representatives Dina Titus (D-NV), David Joyce (R-OH), Ilhan Omar (D-MN) and Greg Steube (R-FL) asked President Trump, Health and Human Services Secretary Robert F. Kennedy Jr., Treasury Secretary Scott Bessent and Attorney General Todd Blanche to provide answers by September 30.
The lawmakers pointed to the Department of Justice’s April 23 order partially rescheduling certain categories of marijuana under the Controlled Substances Act, including FDA-approved marijuana products and marijuana sold through state-licensed medical programs.
“The order marks a significant step in establishing a federal framework for certain state-licensed medical marijuana entities to register and comply with the CSA,” the lawmakers wrote. “We appreciate this development and the progress it reflects toward greater clarity in federal policy.”
However, they said additional guidance is needed as implementation moves forward, particularly regarding “worker protections, patient rights, healthcare coverage, privacy safeguards, home cultivation, and the operation of the new DEA registration system.”
Among the questions raised is how the order will affect patients already participating in state medical marijuana programs. Specifically, the lawmakers asked, “Is medical marijuana cultivated by a patient or their registered caregiver in accordance with state law currently considered a Schedule I or Schedule III substance?”
They also asked whether DOJ anticipates coordinating with the Centers for Medicare & Medicaid Services “regarding Medicare coverage or reimbursement considerations for Schedule III medical marijuana products.”
The lawmakers further requested details on “how, if at all, the framework addresses health insurance reimbursement or coverage for marijuana-based treatments for patients operating in compliance with state medical marijuana laws.”
Another major question involves businesses operating in both medical and recreational marijuana markets, including states where a single or dual license covers both activities. The lawmakers asked how the order will apply to those operators and whether they will remain eligible for federal tax changes associated with Schedule III status.
The lawmakers also raised questions about how Schedule III will affect companies operating in both medical and recreational marijuana markets, particularly in states where the same license covers both activities. “Specifically, will such entities remain eligible for federal tax treatment changes associated with Schedule III status, including relief from Internal Revenue Code Section 280E?” they asked.
Section 280E generally prevents businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, meaning a shift to Schedule III could have major tax implications for qualifying marijuana businesses.
The letter also presses the administration for details on the Drug Enforcement Administration’s planned registration system and how compliance with Schedule III requirements will affect federal enforcement. Lawmakers asked how registration “will be expected to affect federal enforcement with respect to businesses, healthcare providers, workers, and patients.”
They specifically want to know how federal authorities will treat businesses that do not register with the DEA and patients who continue obtaining medical marijuana from state-licensed operators outside the federal system. “How does the Department anticipate federal enforcement will be handled for businesses that do not register with the DEA, and for patients who obtain medical marijuana from state-licensed businesses that are not registered under the federal framework?” the lawmakers asked.
The letter also seeks details on what information will be required to obtain and maintain DEA registration, how the agency will use that information and what privacy protections will be put in place. Lawmakers asked directly, “What safeguards will be in place to prevent misuse of this information?”
“As implementation proceeds, we look forward to continued engagement and await your timely guidance to ensure clarity and consistency across all affected stakeholders,” the lawmakers wrote.
The letter concludes by calling for continued efforts toward “a clear and effective federal marijuana policy.”